Abstract:Abstract Objective To investigate the differential expression profile of lncRNAs in the nonalcoholic fatty liver disease (NAFLD) model induced by oleic acid (OA) and to further explore the role of LINC01260 (ENST00000255183) in NAFLD, providing theoretical support for the clinical value of lncRNAs in NAFLD. Methods OA (50 μg/mL) was used to induce steatosis in normal human LO2 hepatocytes for 48 h and was verified by Oil red O staining. Differential expression profiles of lncRNAs were obtained by eukaryotic circular sequencing (RNA/lncRNA/circRNA-seq) techniques. A gain-of-function (GOF) strategy for LINC01260 was adopted, Oil red O staining and semiquantitative analysis were combined to explore whether the GOF of LINC01260 affects LO2 cell steatosis. CeRNA-based bioinformatics analysis of lncRNAs was performed, and the enriched mRNAs were further verified. RXRB siRNAs were applied and verify its role in LINC01260 regulated OA-induced hepatocytes steatosis. Results Lipid droplets of different sizes were observed in the cells of the OA group. Absorbance in the OA group was significantly increased after isopropanol decolorization ( P < 0.05). Compared with those in the control group, there were 648 lncRNAs with differential expression greater than 1 time in the OA group, of which 351 were upregulated and 297 were downregulated. Fluorescence quantitative PCR showed that the expression of LINC01260 in the OA group was downregulated by 0.35 ± 0.07-fold ( P < 0.05). The formation of lipid droplets in LO2 cells of the LINC01260 GOF group decreased significantly ( P < 0.05). CeRNA analysis indicated that the mRNA levels of RXRB, RNPEPL1, CD82, MADD and KLC2 were changed to different degrees. Overexpression of LINC01260 significantly induced RXRB transcription ( P < 0.05) and translation, and RXRB silence attenuated the lipids decrease induced by LINC01260 overexpression. Conclusion The OA-induced NAFLD cell model has a wide range of lncRNA differential expression profiles. LINC01260 participates in the regulation of the lipid droplet formation process of NAFLD, and its overexpression can significantly inhibit the steatosis process of LO2 cells. Mechanistically, LINC01260 may act as a ceRNA to regulate the expression of RXRB, thereby affecting the adipocytokine signaling pathway.

LncNONMMUG027912 alleviates lipid accumulation through AMPKα/mTOR/SREBP1C axis in nonalcoholic fatty liver

Lnc027912 Reduces Lipid Accumulation Through Akt/MTOR/SREBP1C Axis in Hepatic Cells

Long Non-Coding Rna Profiling In A Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight Into Pathogenesis

Long noncoding RNA lnc_217 regulates hepatic lipid metabolism by modulating lipogenesis and fatty acid oxidation

The Lncrna Gm15622 Stimulates SREBP-1c Expression and Hepatic Lipid Accumulation by Sponging the Mir-742-3p in Mice.

Long non-coding RNAs regulate fatty acid and cholesterol metabolism

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

LB100 Ameliorates Nonalcoholic Fatty Liver Disease Via the AMPK/Sirt1 Pathway.

LncRNA-AK012226 is Involved in Fat Accumulation in Db/db Mice Fatty Liver and Non-alcoholic Fatty Liver Disease Cell Model

Effect of Mirna-10b in Regulating Cellular Steatosis Level by Targeting Ppar-Alpha Expression, A Novel Mechanism for the Pathogenesis of Nafld

LncRNA Gm12664–001 Ameliorates Nonalcoholic Fatty Liver Through Modulating Mir-295-5p and CAV1 Expression

Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism

MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease Through Activating AMPKα

Long Noncoding RNA Lnc-Hc Regulates PPARγ-Mediated Hepatic Lipid Metabolism Through Mir-130B-3p.

The role and possible mechanism of the long noncoding RNA LINC01260 in nonalcoholic fatty liver disease

AMPKα1 Overexpression Alleviates the Hepatocyte Model of Nonalcoholic Fatty Liver Disease Via Inactivating P38mapk Pathway.

Lnc-Hc Ameliorates Steatosis by Promoting Mir-130B-3p Biogenesis and the Assembly of an RNA-induced Silencing Complex.

MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice

NUP85 alleviates lipid metabolism and inflammation by regulating PI3K/AKT signaling pathway in nonalcoholic fatty liver disease

LncRNA Gm28382 promotes lipogenesis by interacting with miR-326-3p to regulate ChREBP signaling pathway in NAFLD